Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control
Open Access
- 14 February 2012
- journal article
- Published by Springer Science and Business Media LLC in Cardiovascular Diabetology
- Vol. 11 (1), 14
- https://doi.org/10.1186/1475-2840-11-14
Abstract
The prognostic benefits of beta-blockers (BB) in patients with systolic heart failure (SHF) are known but despite this, in patients with diabetes they are underutilized. The aim of this study was to assess the effect of beta-blockers (BB) on glycaemic control in patients with Type 2 Diabetes (T2DM) and systolic heart failure (SHF) stratified to beta-1 selective (Bisoprolol) vs. nonselective BB (Carvedilol). This observational, cohort study was conducted in patients with T2DM and SHF attending an Australian tertiary teaching hospital's heart failure services. The primary endpoint was glycaemic control measured by glycosylated haemoglobin (HbA1c) at initiation and top dose of BB. Secondary endpoints included microalbuminuria, changes in lipid profile and estimated glomerular filtration rate (eGFR). 125 patients were assessed. Both groups were well matched for gender, NYHA class and use of guideline validated heart failure and diabetic medications. The mean treatment duration was 1.9 ± 1.1 years with carvedilol and 1.4 ± 1.0 years with bisoprolol (p = ns). The carvedilol group achieved a reduction in HbA1c (7.8 ± 0.21% to 7.3 ± 0.17%, p = 0.02) whereas the bisoprolol group showed no change in HbA1c (7.0 ± 0.20% to 6.9 ± 0.23%, p = 0.92). There was no significant difference in the change in HbA1c from baseline to peak BB dose in the carvedilol group compared to the bisoprolol group. There was a similar deterioration in eGFR, but no significant changes in lipid profile or microalbuminuria in both groups (p = ns). BB use did not worsen glycaemic control, lipid profile or albuminuria status in subjects with SHF and T2DM. Carvedilol significantly improved glycemic control in subjects with SHF and T2DM and this improvement was non significantly better than that obtained with bisoprolol. BB's should not be withheld from patients with T2DM and SHF.Keywords
This publication has 25 references indexed in Scilit:
- Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure-a randomized studyCardiovascular Diabetology, 2011
- Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized studyCardiovascular Diabetology, 2010
- Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patientsDiabetes, Obesity and Metabolism, 2009
- Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertensionJournal of Diabetes and its Complications, 2008
- Differential effect of β‐blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINIDiabetic Medicine, 2007
- Prescription patterns in patients with systolic heart failure at hospital discharge: why beta blockers are underprescribed or prescribed at low dose in real life?International Journal of Clinical Practice, 2007
- Differential Effects of β-Blockers on Albuminuria in Patients With Type 2 DiabetesHypertension, 2005
- ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure)Journal of the American College of Cardiology, 2005
- Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trialsAmerican Heart Journal, 2003
- Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.BMJ, 1989